Form 8-K - Current report:
SEC Accession No. 0001193125-25-026683
Filing Date
2025-02-14
Accepted
2025-02-14 08:38:17
Documents
15
Period of Report
2025-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875089d8k.htm   iXBRL 8-K 29160
2 EX-10.1 d875089dex101.htm EX-10.1 947232
6 GRAPHIC g875089g0214013949167.jpg GRAPHIC 2847
  Complete submission text file 0001193125-25-026683.txt   1337627

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srpt-20250213.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20250213_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20250213_pre.xml EX-101.PRE 10813
17 EXTRACTED XBRL INSTANCE DOCUMENT d875089d8k_htm.xml XML 3503
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 25623505
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)